Nephros Inc. continues to advance its ultrafiltration water treatment solutions through an exclusive license and supply agreement with Italy-based Medica S.p.A., solidifying its technological moat. The company’s business model centers on proprietary filtration products that depend heavily on third-party contractors for installation and servicing—a critical factor for product performance and regulatory compliance. While recent financial results show profitability supported by strong liquidity, the firm faces operational risk from contractor dependency and a disclosed material weakness in revenue recognition controls. Growth drivers include expanding product innovation such as the HydraGuard UltraFilter and securing long-term supply commitments with Medica. Maintaining product quality and managing third-party service standards remain key challenges as Nephros seeks scalable growth in a specialized filtration market.